Tomasz Sablinski
Chief Executive Officer and Co-founder, Transparency Life Sciences
Meet Tomasz Sablinski
According to Tomasz, meaningful progress in making new therapies available to patients will be driven by the convergence of modern technology and science. “The industry must realize that the digital revolution does apply to drug development. And in practice, companies must become quicker at adopting a digital approach to clinical research, otherwise, big and small technology players will make them irrelevant.”